Found: 133
Select item for more details and to access through your institution.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
- Published in:
- 2018
- By:
- Publication type:
- journal article
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The evolving landscape of tissue‐agnostic therapies in precision oncology.
- Published in:
- CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 5, p. 433, doi. 10.3322/caac.21844
- By:
- Publication type:
- Article
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z
- By:
- Publication type:
- Article
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 576, doi. 10.1007/s10637-017-0459-7
- By:
- Publication type:
- Article
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
- Published in:
- 2017
- By:
- Publication type:
- Erratum
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 2, p. 216, doi. 10.1007/s10637-016-0327-x
- By:
- Publication type:
- Article
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1187, doi. 10.1007/s10637-015-0278-7
- By:
- Publication type:
- Article
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 463, doi. 10.1007/s10637-015-0218-6
- By:
- Publication type:
- Article
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 187, doi. 10.1007/s10637-014-0177-3
- By:
- Publication type:
- Article
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 135, doi. 10.1007/s10637-013-9952-9
- By:
- Publication type:
- Article
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 87, doi. 10.1007/s10637-013-9949-4
- By:
- Publication type:
- Article
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 891, doi. 10.1007/s10637-012-9887-6
- By:
- Publication type:
- Article
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 927, doi. 10.1007/s10637-012-9900-0
- By:
- Publication type:
- Article
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 363, doi. 10.1007/s10637-012-9823-9
- By:
- Publication type:
- Article
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 3, p. 467, doi. 10.1007/s10637-009-9374-x
- By:
- Publication type:
- Article
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 1, p. 75, doi. 10.1007/s10637-008-9160-1
- By:
- Publication type:
- Article
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
- Published in:
- Journal of Neuro-Oncology, 2019, v. 144, n. 2, p. 303, doi. 10.1007/s11060-019-03227-7
- By:
- Publication type:
- Article
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
- Published in:
- Journal of Neuro-Oncology, 2016, v. 129, n. 2, p. 281, doi. 10.1007/s11060-016-2172-3
- By:
- Publication type:
- Article
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 9, p. 654, doi. 10.1093/jnci/djt026
- By:
- Publication type:
- Article
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 7, p. 1131, doi. 10.1038/s41416-023-02436-2
- By:
- Publication type:
- Article
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
- Published in:
- British Journal of Cancer, 2023, v. 128, n. 10, p. 1906, doi. 10.1038/s41416-023-02185-2
- By:
- Publication type:
- Article
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
- Published in:
- British Journal of Cancer, 2023, v. 128, n. 2, p. 255, doi. 10.1038/s41416-022-02022-y
- By:
- Publication type:
- Article
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Everolimus Plus Exemestane in Postmenopausal Patients with HR<sup>+</sup> Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- Published in:
- Advances in Therapy, 2013, v. 30, n. 10, p. 870, doi. 10.1007/s12325-013-0060-1
- By:
- Publication type:
- Article
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 204, n. 1, p. 123, doi. 10.1007/s10549-023-07167-9
- By:
- Publication type:
- Article
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 203, n. 3, p. 123, doi. 10.1007/s10549-023-07167-9
- By:
- Publication type:
- Article
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 170, n. 3, p. 535, doi. 10.1007/s10549-018-4769-z
- By:
- Publication type:
- Article
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 167, n. 3, p. 659, doi. 10.1007/s10549-017-4523-y
- By:
- Publication type:
- Article
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 2, p. 299, doi. 10.1007/s10549-015-3613-y
- By:
- Publication type:
- Article
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 2, p. 287, doi. 10.1007/s10549-015-3615-9
- By:
- Publication type:
- Article
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 1, p. 89, doi. 10.1007/s10549-015-3599-5
- By:
- Publication type:
- Article
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 149, n. 1, p. 151, doi. 10.1007/s10549-014-3248-4
- By:
- Publication type:
- Article
Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 148, n. 3, p. 535, doi. 10.1007/s10549-014-3189-y
- By:
- Publication type:
- Article
Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
- Published in:
- 2013
- By:
- Publication type:
- Report
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
- Published in:
- European Journal of Clinical Pharmacology, 2013, v. 69, n. 12, p. 2073, doi. 10.1007/s00228-013-1580-y
- By:
- Publication type:
- Article
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 1, p. 107, doi. 10.1002/cpdd.575
- By:
- Publication type:
- Article
Relative Bioavailability of Pediatric Oral Solution and Tablet Formulations of Trametinib in Adult Patients With Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 4, p. 287, doi. 10.1002/cpdd.152
- By:
- Publication type:
- Article
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.
- Published in:
- Oncologist, 2023, v. 28, n. 7, p. 640, doi. 10.1093/oncolo/oyad029
- By:
- Publication type:
- Article
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
- Published in:
- Oncologist, 2022, v. 27, n. 3, p. 175, doi. 10.1093/oncolo/oyab064
- By:
- Publication type:
- Article